040101892026 - TOCILIZUMAB 20 MG/ML SOL INJ - CLINICAL JUSTIFICATION OF BRAND PER PATIENT

This tender, identified by reference number 040101892026, relates to the procurement of Tocilizumab 20 mg/ml solution for injection. A key aspect of this tender is the requirement for a 'clinical justification of brand per patient'. This indicates that the procurement process may involve specific clinical criteria or a justification process for selecting a particular brand of Tocilizumab for individual patients. Tocilizumab is a medication used to treat various inflammatory conditions, such as rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome. The contracting authority, likely a hospital or healthcare provider, is seeking to ensure the appropriate and cost-effective use of this medication. The tender may involve establishing a framework agreement or a direct purchase where the choice of brand is contingent upon specific patient needs, clinical efficacy, or formulary guidelines. The objective is to secure a reliable supply of Tocilizumab while ensuring that its use is clinically validated and optimized for each patient's treatment plan.

This is a supplies contract in the health and medical services and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 98,320.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.